Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers

Visweswaran Navaratnam · Surash Ramanathan · Mohd Suhaimi Ab. Wahab · Gan Siew Hua · Sharif Mahsufi Mansor · Jean-René Kiechel · Michel Vaillant · Walter R. J. Taylor · Piero Olliaro

Received: 13 August 2008 / Accepted: 2 April 2009 / Published online: 30 April 2009 © The Author(s) 2009. This article is published with open access at Springerlink.com

Abstract
Objective There is limited pharmacokinetic data available for the combination artesunate + amodiaquine, which is used widely to treat uncomplicated malaria. This study examines the bioavailability and tolerability of a fixed (200 mg artesunate + 540 mg amodiaquine) and loose (200 mg + 612 mg) combination with a 2 × 2 cross-over design in 24 healthy volunteers.

Methods Parent compounds and metabolites [dihydroartemisinin (DHA) and desethylamodiaquine (DEAQ)] were measured by high-performance liquid chromatography–electrochemical detection, and the area under the curve (AUC)₀⁻₉ and C₉₉₉ were compared by an analysis of variance (ANOVA) based on geometric least square means using the Schuirmann two one-sided test.

Results The AUC₀⁻₉ for total DHA and DEAQ were 1522 ± 633 and 30021 ± 14211 ng h/ml for the fixed products and 1688 ± 767 and 40261 ± 19824 ng h/ml (mean ± standard deviation) for the loose products. The ANOVA showed no statistical differences except for sequence effect for DHA.

Electronic supplementary material The online version of this article (doi:10.1007/s00228-009-0656-1) contains supplementary material, which is available to authorized users.

V. Navaratnam · S. Ramanathan · S. M. Mansor
National Center for Drug Research (CRD), Universiti Sains Malaysia (USM), 11800 Minden, Pulau Pinang, Penang, Malaysia

M. S. A. Wahab · G. Siew Hua
Pharmacology Laboratory, CTU-Clinical Trial Unit, School of Medical Sciences, Health Campus, Hospital Universiti Sains Malaysia (HUSM), Kubang Kerian, Kota Bharu 16150 Kelantan, Malaysia

M. Vaillant
Centre for Health Studies, Public Research Centre–Health, 18 Dicks Street, 1417 Luxembourg, Germany

M. Vaillant
Unité 3677, Bases thérapeutiques des inflammations, Université Victor Segalen Bordeaux II, Bordeaux, France

W. R. J. Taylor
Service de Médecine Internationale et Humanitaire, Hôpitaux Universitaires de Genève, Genève 14, Suisse

P. Olliaro
UNICEF/UNDP/WB/WHO Special Programme for Research & Training in Tropical Diseases (TDR), 20, Avenue Appia, Geneva 27 1211, Switzerland
e-mail: olliarop@who.int
The values obtained with the fixed product were within the 125% bioequivalent limits but extend below the 80% bioequivalence limits.

**Conclusion** Both combinations were well tolerated and had comparable pharmacokinetic profiles; differences are unlikely to be clinically relevant.

**Keywords** Amodiaquine · Artesunate · Fixed combination treatment · Pharmacokinetics · Non-fixed combination treatment · Tolerability

**Introduction**

Malaria occurs in 109 countries with 3.3 billion people at risk of contracting the disease; 247 million cases of malaria are reported annually [1]. The World Health Organisation (WHO) recommends replacing monotherapies with artemisinin combination therapies (ACTs) [2]. According to official figures, 49 million ACT courses were distributed in 2006, but real usage is likely to be much higher [1].

Artesunate (AS) combined with amodiaquine (AQ) is currently one of the most widely used ACTs and has been adopted by 20 countries worldwide (19 in Africa) as the first line treatment for malaria. Both AS and AQ are currently administered as a loose formulation or in blister packs; however, due to the large number of tablets involved, there is a possibility of patients failing to adhere to their treatment regimen or complete their course of therapy. To overcome this, a fixed-dose combination treatment (AS/AQ) that provides a simplified regimen has been developed and registered.

Artesunate and AQ have independent but complementary modes of action: the former is a short-lived, highly potent artemisinin that provides a rapid reduction of parasite biomass, whereas the latter has a longer half-life to ensure the eradication of residual parasites [3]. Amodiaquine [dihydroartemisinin-10α-hemisuccinate, molecular weight (MW) 384] is considered to be a prodrug, as it is rapidly and extensively converted via chemical and enzymatic pathways to its main bioactive metabolite, dihydroartemisinin (DHA; also referred to as artenimol, MW 284). Following oral intake, AS levels are transient, and DHA is the predominant species; the two moieties are roughly equipotent [4], and both contribute to parasite killing. The pharmacology of AS and DHA, following oral administration of AS and DHA, show considerable inter-individual variation and are affected by disease status [5, 6]. The elimination half-life ($t_{1/2}$) of DHA averages 0.65–2.59 h [7, 8]. Amodiaquine is also considered to be a prodrug and is rapidly and extensively converted to its main metabolite, N-desethylamodiaquine (DEAQ), essentially in the liver by cytochrome P 2C8 (CYP2C8) [9]. Unlike AS, AQ has a negligible effect on parasites. In adults, the elimination half-life of AQ is approximately 4 h [10], but DEAQ has a much longer but variable half-life (2.5–18.2 days) [11, 12].

The pharmacology of oral AS, often co-administered with mefloquine, has been studied in both healthy volunteers and malaria patients. In contrast, despite years of widespread use either alone or combined with AS, pharmacological information on AQ is inadequate.

The aim of this study was to investigate the pharmacokinetic properties, tolerability, and bioavailability of AS and AQ when co-administered as either fixed or non-fixed products in healthy normal volunteers.

**Methods**

**Study design**

This was an open, randomised, two-period crossover trial in which the PK properties, tolerability and bioavailability of AS + AQ when administered as a fixed-dose or non-fixed dose preparation were compared. The study was conducted in accordance with international Good Clinical Practice standards and monitored. The protocol was approved by the Institution Ethical Review Board of the Teaching Hospital Universiti Sains Malaysia, Kota Bharu, Malaysia and the WHO Ethics Committee, and was authorised by the Malaysian Ministry of Health.

A total of 24 healthy normal volunteers (HNVs), aged between 21 and 45 years, were randomised to receive either the non-fixed (NF) or the fixed (F) combination regimen during Study Period 1. The randomisation process was carried out by using a table of random numbers to select 24 consecutive, unduplicated numbers between 01 and 24. After a wash-out period of 60 days ($5 \times t_{1/2}$; DEAQ 45–90 days), subjects entered Study Period 2 and were given the alternative treatment combination. Thus, one group of subjects received the fixed, followed by the non-fixed combination (F–NF), while the other group received the non-fixed, followed by the fixed product (NF–F).

Drugs were administered under fasting conditions. Each subject received a single total dose of 200 mg AS plus 540 mg AQ when given the fixed product, and 200 mg AS plus 612 mg AQ with the non-fixed product. These doses represent 1 day of a 3-day therapeutic course and were selected to be as close as possible to the target treatment doses of 4 and 10 mg kg$^{-1}$ day$^{-1}$ for AS and AQ, respectively. The doses of AQ in the fixed and non-fixed formulations were different because of the different strengths of the formulations used.
Study drugs

The fixed-dose co-formulated product (manufactured by Creapharm, France, batch no. CPM 5856) consisted of 100 mg AS and 270 mg AQ base; the loose non-fixed product consisted of AS (Arsumax 50 mg tablets; Sanofi-Aventis, Paris, France/Guilin Pharma Co, China, batch no. 31201) and AQ (Flavoquin 153 mg of AQ base; Hoechst Marion Roussel, Sanofi-Aventis, batch no. 4).

Entry criteria

Volunteers were recruited by means of advertisements placed at the teaching hospital of the Universiti Sains Malaysia, Kota Bahru. Written informed consent was required before the volunteers were allowed to participate in the trials. Entry criteria included a negative pregnancy test for women; a negative malaria thick smear; no significant abnormal findings on the medical history or clinical examination (including electrocardiogram, haematology, liver and renal function tests); no history of antimalarial treatment in the preceding 2 months; no other drugs or medications in the preceding week; adequate venous access; no abuse of alcohol or recreational drugs; no known allergy to the study drugs; smokers (>10/day) were also excluded.

Drug assay

Sampling

Blood samples were collected at pre-dose, at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h post-medication and at 5, 7, 14, 21, 28, 35, 42 and 60 days post-medication. Day 60 for Study Period 1 and Day 0 for Study Period 2 coincided. Specimens in the first 12 h of each study period were drawn via an indwelling catheter; for the remaining periods, blood samples were drawn by direct venipuncture. Blood samples (5 ml each) were stored in heparinised vacutainer tubes for further processing. The levels of AQ and DEAQ were measured at all time points, while those of AS and DHA were measured at pre-dose and at 0.25, 0.50, 0.75, 1.0, 1.5, 2, 3, 4, 6, 8 and 12 h after drug administration. After centrifugation of blood samples, the plasma samples were immediately transferred to separate, appropriately labelled plastic cryotubes and frozen at −70°C.

Analytical methods

The assays were carried out at the Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia.

Artesunate and dihydroartemisinin This assay method was validated with minor modifications of a previously published method [13]. The analyses of AS and DHA were carried out on BAS 200A high-performance liquid chromatography/electrochemical (HPLC–EC; BAS, West Lafayette, IN) systems operating at reductive mode. Chromatographic separation of AS, DHA and the internal standard artemisinin (QHS) was obtained at room temperature (25°C) on an Inertsil C4 column (internal diameter 150×4.6 mm, particle size 5 μm; GL Sciences, Tokyo, Japan). The mobile phase consisted of acetonitrile (ACN) and 0.05 M acetic acid (40:60 %v/v) adjusted to pH 4.0 with 1 M NaOH. The flow rate was 1.50 ml/min. Detection was performed in the reductive mode at −1000 mV in an oxygen-free environment. The HPLC-EC (reductive) system produced a linear response for the concentration of AS and DHA varying from 20 to 1600 ng/ml respectively. The extraction recoveries of AS, DHA and QHS were above 79% with a coefficient of variation (CV) not exceeding 13%. The lower limit of quantification (LLOQ) of AS was 20 ng/ml, and its accuracy and CV were −0.1 and 4.4%, respectively; the corresponding values for DHA (LLOQ 20 ng/ml) were −2.6 and 6.0%, respectively. The within-day and day-to-day precision for both AS and DHA at low, medium and high concentrations did not exceed 15%.

Amodiaquine and N-desethylamodiaquine The analyses of AQ and DEAQ were carried out on BAS 200A HPLC–EC systems coupled to an EC detector operating at oxidative mode. The analysis of AQ, DEAQ and the IB-DEAQ (internal standard) was carried out at room temperature (25°C) using an Inertsil C4 column (internal diameter 150×4.6 mm, particle size 5 μm; GL Sciences). The mobile phase consisted of ACN and 0.05 M KH2PO4 (11:89, %v/v) adjusted to pH 4.0 with orthophosphoric acid. The flow rate was 1.0 ml/min. Detection was performed in the oxidative mode at +800 mV. The extraction recoveries of AQ, DEAQ and IB-DEAQ were all above 80%, with a CV of less than 11%. The HPLC–EC (oxidative) system produced a linear response for the concentration of AQ and DEAQ that varied from 20 to 1600 ng/ml, respectively. The LLOQ of AQ and DEAQ were 20 ng/ml, and the accuracy and variation were of 4.2 and 5.0%, respectively; the CV were 7.5 and 7.3%, respectively. The within-day and day-to-day precision for both AQ and DEAQ were less than 15%.

Pharmacokinetic analyses

We measured the parent drug and main active metabolite of both compounds (AS + DHA and AQ + DEAQ). In addition, the total DHA concentration was estimated by summation of HPLC-determined DHA and DHA equiva-
Pharmacokinetic measures, such as AUC and \(C_{\text{max}}\), the FDA guidance recommends that the statistical analysis for bioequivalence studies, the 1992 Federal Drug Agency curve. AUMC is the area under the first moment-versus-time compounds and metabolites as the AUMC/AUC where residence time (MRT) was calculated for both parent. The pharmacokinetic parameters \(C_{\text{max}}\), \(T_{\text{max}}\), and AUC0-t were determined using model independent formulae \[14\]. Maximum achieved concentration (\(C_{\text{max}}\)) and time to achieve the maximum concentration (\(T_{\text{max}}\)) were obtained from a visual inspection of the plasma concentration versus time curve. Area under the concentration-time curve from 0 to \(t\) (AUC0-t, where \(t =\) last quantifiable drug concentration) was calculated using the linear trapezoidal rule; AUC0-t=\([([C_1+C_2]/2(t_2 - t_1)]+...+[C_{n-1}+C_n]/2(t_{n} - t_{n-1}))\). The AUC0-\(\infty\) (up to infinity) was calculated by the formula \(\text{AUC}_{0-\infty} = \text{C}_t / \lambda z\) where \(C_t\) is the concentration at the last quantifiable time. From the terminal log-linear (disposition) phase, a first order elimination rate constant (\(\lambda z\)) was estimated by linear regression and terminal half-life value (\(t_{1/2}\)) was estimated from at least three concentration values using the equation \(t_{1/2} = \ln 2 / \lambda z\). The mean residence time (MRT) was calculated for both parent compounds and metabolites as the AUMC/AUC where AUMC is the area under the first moment-versus-time curve.

Bioavailability

For bioequivalence studies, the 1992 Federal Drug Agency (FDA) guidance recommends that the statistical analysis for pharmacokinetic measures, such as AUC and \(C_{\text{max}}\), be based on the two one-sided tests procedure that examines whether the average values for the pharmacokinetic measures determined after administration of the test and reference products were comparable. This approach is termed average bioequivalence and involves the calculation of a 90% confidence interval (CI) for the ratio of the averages (population geometric means) of the measures for the test and reference products. To establish bioequivalence, the calculated confidence interval should fall within a limit, usually between 80 and 125%, for the ratio of the product averages \[16\]. This method is equivalent to the corresponding two one-sided tests procedure with the null hypothesis of bioinequivalence at the 5% significance level \[17\].

Bioavailabilities of the fixed and non-fixed AS/AQ formulations were compared using mean \(\text{AUC}_{0-4}\). In addition, we tested the \(C_{\text{max}}\), \(T_{\text{max}}\) and \(t_{1/2}\). Differences in the ln mean \(\text{AUC}_{0-4}\) and ln mean \(C_{\text{max}}\) between treatment periods were compared using analysis of variance (ANOVA). The model allowed for the effects of formulation, period, sequence and subjects within sequence on the observed parameter.

For \(\text{AUC}_{0-4}\) and \(C_{\text{max}}\), we applied the Schuirmann’s two one-sided tests (TOST) to compute the probability to reject the null hypothesis (i.e. that the two products are different). The \(T_{\text{max}}\) and \(t_{1/2}\) values were compared by the Wilcoxon signed rank test. All statistical analyses were performed with the statistical software package EquivTest ver. 2.0 \[15\].

Safety

We used standard definitions for adverse events (AEs) and serious adverse events (SAEs). All subjects were assessed clinically at baseline. Reporting of symptoms was solicited during the course of the study. Clinical AEs were described by the attending physician in terms of signs and symptoms and classed by body system: gastrointestinal (GI), cardiovascular (CVS), central nervous system (CNS), etc. They were assessed for severity [mild (Grade 1), moderate (Grade 2), severe (Grade 3), very severe (Grade 4)] using the Common Toxicity Criteria (CTC V3.0; National Institute of Health, Bethesda, MD).

Laboratory examinations (haematology, liver and renal functions) were conducted at Day 0, Day 7 and Day 28 of each study period. Twelve lead electrocardiograms (ECGs) were performed at baseline and at 1, 2, 4, and 24 h post-drug administration; this was repeated for Study Period 2 (results to be reported in a separate analysis). All AEs that occurred during the study were recorded with the date and time of occurrence and the date the abnormal finding disappeared.

The chi-squared test was used to compare the frequencies of: (1) AEs between groups and (2) normal/abnormal laboratory values in shift tables. The Cochran–Mantel– Haentzel statistic was used to assess the general association of the treatment groups and the occurrence of at least one AE in a subject during the two study periods.

Results

Disposition and baseline characteristics

Study subject disposition is shown in Fig. 1. Two subjects were excluded from the overall data analysis: one subject received only the non-fixed AS/AQ combination in Study Period 1, but was later withdrawn from the study because of acute gouty arthritis (this event was a recrudescence of prior disease that was judged to be probably related to the study drug); the other subject had an extraordinarily high DEAQ AUC0-t (approx. ten10-fold higher than that with the fixed combination) after having received the non-fixed combination. This observation was deemed to be an unexplainable outlying result, and all pharmacokinetic data pertaining to this subject were excluded from the analyses. The threshold for outliers was calculated as recommended.
for skewed distributions from the interquartile range. Inclusion of this subject’s data in the analyses did not alter any bioequivalence conclusions (data not shown). Therefore, 23 of the original 24 subjects were analysed for drug disposition (six males, 17 females) and 22 for comparative bioavailability.

The mean age of the subjects was 27.3±6.8 years. Medical history and vital signs were similar in the two groups except pulse rate ($p=0.02$).

**Pharmacokinetics**

After oral administration, AS and AQ were rapidly absorbed and underwent rapid and extensive metabolism to their respective metabolites, DHA and DEAQ. The plasma levels of both DHA and DEAQ were manifold higher and persisted for longer than their respective parent compounds. The pharmacokinetic properties of AS, DHA, AQ, DEAQ and total DHA are given in Table 1; the plasma time–concentration profiles of AS, DHA, AQ and DEAQ are shown in Fig. 2.

The relative bioavailabilities of total DHA and DEAQ expressed as AUC$_{0-t}$ produced by the fixed product were similar to those of the non-fixed product (F:NF ratios 102.3 and 107%, respectively). The analysis of comparative bioavailability of the two products is shown in Table 2. There was no evidence of carry-over effects between subjects except for the AQ (parent) AUC, no period effect except for total DHA AUC and no drug effects within subjects between the two formulations except a marginal effect for AQ and DEQA AUC. For both total DHA and DEAQ, the AUC$_{0-t}$ values obtained with the fixed

| Compound          | Product         | C$_{max}$ (ng/ml) | T$_{max}$ (h) | AUC$_{0-t}$ (ng h/ml) | AUC$_{0-\infty}$ (ng h/ml) | MRT (h) | Extra (%) | T$_{1/2}$ (h) | MRT (h) |
|-------------------|-----------------|-------------------|---------------|-----------------------|----------------------------|---------|-----------|---------------|---------|
| Artesunate (AS)   | Fixed           | 333±233           | 0.26±0.05     | 213.2±139.8           | 201.5±133.4                | 17.8±11.3 | 0.63±0.55 | 0.65±0.55     | 0.94±0.57 |
|                   | Non-fixed       | 444±425           | 0.53±0.39     | 391.1±247.2           | 48.6±29.1                  | 16.5±11.4 | 0.76±0.6  | 1.05±0.72     | 1.05±0.72 |
|                   |                 | 609.8±282.8       | 0.56±0.39     | 1.468.9±579.9         | 99.6±63.8                  | 7.4±4.8  | 1.68±1.1  | 2.6±1.0       | 2.6±1.0  |
| Dihydroartemisinin (DHA) | Fixed           | 594.6±251         | 0.57±0.39     | 1.468.9±579.9         | 99.6±63.8                  | 7.4±4.8  | 1.68±1.1  | 2.6±1.0       | 2.6±1.0  |
|                   | Non-fixed       | 874.5±621.5       | 1.05±0.95     | 1.680.6±673.5         | 87.2±44.3                  | 5.7±3.5  | 1.7±0.9   | 2.3±0.7       | 2.3±0.7  |
|                   |                 | 1.309.4±643.4     | 0.57±0.39     | 1.468.9±579.9         | 99.6±63.8                  | 7.4±4.8  | 1.68±1.1  | 2.6±1.0       | 2.6±1.0  |
|                   |                 | 1.584.0±673.5     | 0.57±0.39     | 1.468.9±579.9         | 99.6±63.8                  | 7.4±4.8  | 1.68±1.1  | 2.6±1.0       | 2.6±1.0  |
|                   |                 | 1.801.4±789.0     | 0.57±0.39     | 1.468.9±579.9         | 99.6±63.8                  | 7.4±4.8  | 1.68±1.1  | 2.6±1.0       | 2.6±1.0  |
|                   |                 | 2.153.1±172.0     | 0.57±0.39     | 1.468.9±579.9         | 99.6±63.8                  | 7.4±4.8  | 1.68±1.1  | 2.6±1.0       | 2.6±1.0  |
| Total dihydroartemisinin equivalents | Fixed           | 201.5±139.8       | 0.26±0.05     | 342.2±25.1            | 34.2±25.1                  | 17.8±11.3 | 0.63±0.55 | 0.65±0.55     | 0.94±0.57 |
|                   | Non-fixed       | 391.1±247.2       | 0.53±0.39     | 48.6±29.1             | 16.5±11.4                  | 0.76±0.6  | 1.05±0.72 | 1.05±0.72     | 1.05±0.72 |
|                   |                 | 1.468.9±579.9     | 0.56±0.39     | 99.6±63.8             | 7.4±4.8                    | 1.68±1.1  | 2.6±1.0   | 2.6±1.0       | 2.6±1.0  |
|                   |                 | 1.680.6±673.5     | 0.57±0.39     | 87.2±44.3             | 5.7±3.5                    | 1.7±0.9   | 2.3±0.7   | 2.3±0.7       | 2.3±0.7  |
|                   |                 | 1.801.4±789.0     | 0.57±0.39     | 77.9±41.8             | 4.8±2.4                    | 1.3±0.7   | 2.1±0.7   | 2.1±0.7       | 2.1±0.7  |
|                   |                 | 2.153.1±172.0     | 0.57±0.39     | 77.9±41.8             | 4.8±2.4                    | 1.3±0.7   | 2.1±0.7   | 2.1±0.7       | 2.1±0.7  |
|                   |                 | 3.002.1±142.1     | 0.57±0.39     | 13.378.1±13.303       | 22.2±11.6                  | 22.1±11.6 | 2.1±0.7   | 2.1±0.7       | 2.1±0.7  |
|                   |                 | 3.045.4±196.9     | 0.57±0.39     | 13.378.1±13.303       | 22.2±11.6                  | 22.1±11.6 | 2.1±0.7   | 2.1±0.7       | 2.1±0.7  |
|                   |                 | 3.8462±6.401      | 0.57±0.39     | 13.378.1±13.303       | 22.2±11.6                  | 22.1±11.6 | 2.1±0.7   | 2.1±0.7       | 2.1±0.7  |

MRT, Mean residence time; SD, standard deviation

Data are presented as the mean ± SD of non-normalised data

See the Methods section, subsection Bioavailability for definition of pharmacokinetic measures
combination lie within the 95% CI of the non-fixed products [data not shown: provided as Electronic Supplementary Material (ESM)]. The values produced by the fixed product appear to be tighter than those provided by the non-fixed product for both total DHA and DEAQ (data not shown: provided as ESM).

Based on the 90% CI of the geometric least squares means ratios (GLSMR), the $C_{\text{max}}$ and $\text{AUC}_{0-t}$ values produced with the fixed combination with respect to the non-fixed combination were within the upper boundary (125%) but extended beyond the lower boundary (80%) of the confidence interval for all moieties except AS $C_{\text{max}}$, which was also $>125\%$ (Table 2). The Shuirmann TOST was non-significant for lower limits, while the upper limits of the one-tailed $t$-statistics were significant (again except for AS $C_{\text{max}}$) (Table 2). Plasma $C_{\text{max}}$ and $\text{AUC}_{0-t}$ of total DHA were lower in the fixed combination by 12 and 8%, respectively, for total DHA and by 15 and 14%, respectively, for DEAQ. The $T_{\text{max}}$ was significantly shorter in subjects given the fixed product for total DHA, AS and DHA, longer for AQ and not different for DEAQ (Table 2). The within-subject variation (% CV) of the $\text{AUC}_{0-t}$ between the non-fixed and the fixed combination were 4.3% for total DHA and 3.6% for DEAQ. The $t_{1/2}$ for both formulations was not bioequivalent (Table 2).

Mean residence times (see Table 1) were compared between the fixed and non-fixed combination for AS, DHA, AQ and DEAQ using a $t$ test. The comparisons were found to be non-significant. The mean ± standard deviation $\text{AUC}$ ratios AS:DHA were 0.08±0.12 and 0.09±0.06 for the fixed and non-fixed product, respectively; the corresponding values for AQ:DEAQ were 0.002±0.002 and 0.003±0.004, respectively, with no difference between the two formulations.
When individual subjects were considered, there was no consistent direction of change in any parameter measured. Figure 3 depicts individual data with the two products of AUC0-t for total DHA and DEAQ. The ranges of values were similar for the fixed and non-fixed combination, and changes went both ways between the two combinations: for DHA and DEAQ, values increased in 46 and 35% of patients, respectively, and decreased in 54 and 65%, respectively.

Safety

Both formulations were tolerated. Overall, 42 events were reported. During Study Periods 1 and 2, 45 and 55% of subjects had at least one AE. By drug group, the proportions were: (1) 67 (F) versus 36% (NF) in Study Period 1, and (2) 45 (F) versus 58% (NF) in Study Period 2.

There was no statistically significant difference between sequences (62 and 41% of subjects in the F–NF and NF–F sequences had at least one AE, $p=0.14$) or between Study Period 1 and 2 ($p=1.0$). The Cochran–Mantel–Haentzel statistic for a general association of the treatment groups and the occurrence of at least one AE in a subject during the two periods of the study showed no significant difference ($p=0.56$).

The most common AEs were liver enzyme abnormalities (21% of all AEs), flushing (17%), dizziness and giddiness (14% each) and nausea (7%); all other events contributed <5%. The body systems most commonly affected were the gastro-intestinal system (35% of AEs including liver enzyme abnormalities) and the central and peripheral nervous system (30% of all AEs).

There was no significant difference in the drug–event relationship between the two groups: 10/23 events in Group 1 and 13/20 in Group 2 were judged to be probably or definitely related to study drug (43 and 65%, respectively).

The main laboratory parameters monitored during the study are presented in Table 3. At screening, 18 subjects had mildly abnormal laboratory values (Grade 1) and one subject exhibited a Grade 2 alanine transaminase (ALT) concentration. Pre-treatment, there was one case of Grade 1 neutropaenia ($1600 \times 10^6/l$) in the group that received the non-fixed combination first; this subject returned to normal by Day 7 of Study Period 1. One subject was inadvertently
enrolled with a Grade 2 baseline value of ALT; this also normalised during follow-up.

Four subjects presented five abnormal laboratory values during the study: three were Grade 3 and two were Grade 4. One subject with a baseline uric acid value of 546 μmol/l experienced two episodes of Grade 4 (uric acid > 590 μmol/l) elevation in uric acid at Day 7 and 29 of Study Period 1, with values of 598 μmol/l and 636 μmol/l, respectively. This patient had a history of gout arthritis and was withdrawn from the study after Study Period 1.

Three individuals had one Grade 3 deviation each: (1) ALT = 156 U/L (5–20 × upper normal limit) at Day 60 of Study Period 2 (sequence NF–F); (2) hypocalcaemia calcium=1.67 mmol/l (1.5–1.75 × upper limit) (sequence NF–F); (3) hyponatraemia sodium=124 mmol/l (120–130 × upper limit) at Day 7 of Study Period 1. No volunteers developed neutropaenia during follow-up.

No serious AEs occurred. One subject was withdrawn due to an exacerbation of pre-existing gout which had not been declared or detected on recruitment. The subject was treated with non-steroidal anti-inflammatory drugs and ultimately recovered.

**Discussion**

The results of this study on adult Malaysian healthy volunteers using a cross-over design shows that AS and AQ are readily absorbed and well tolerated when co-administered either as loose products (in a non-fixed combination) or as a fixed-dose combination. However, the two combinations cannot strictly be defined as "bioequivalent".

We measured and reported the disposition of the parent compounds and their metabolites separately, but we...
considered the primary analytes (total DHA for AS, and DEAQ for AQ), as the biologically and clinically relevant indicators of drug absorption. For AS and DHA, the reason for combining the two measurements (after stoichiometrical conversion of the measured AS values) is that the two compounds have comparable antimalarial potencies [4] and conversion of AS to DHA is rapid (chemical hydrolysis starts in the stomach). This makes their pharmacological effects indistinguishable over their very short residence time. This approach is supported by the correlation between the bioassay and the measurement of the two separate products [18], the combined measurement may be the better parameter to use for pharmacokinetic–pharmacodynamic analyses. Although AQ is more potent in vitro than its metabolite, the systemic exposure to AQ is considerably lower than that to DEAQ [10, 12], which is solely responsible for sustained antimalarial activity after AS/DHA have been eliminated. The ratio between the AUCs of AS to DHA and AQ to DEAQ was approximately 8.5% and 0.02%, respectively; the AQ $t_{1/2}$ was one tenth of that for DEAQ.

In this study we used different descriptive and statistical approaches to assess and compare the product bioavailabilities, and these generally gave consistent results. It is commonly accepted that the two primary parameters used for measuring the extent of drug absorption are area under the curve (AUC) and maximum concentration ($C_{\text{max}}$), both logarithmically transformed. To confirm bioequivalence of the two products, the geometric mean ratios (plus 90% CI) of these metrics should lie within an 80–125% window of acceptance [16]. We used the ANOVA $F$ test to identify the source of variance, be it a product, subject or period effect.
**Table 3** Laboratory parameter measures by product over time

| Laboratory parameters          | Product | Baseline | Day 8      | Day 29     | Day 60     |
|-------------------------------|---------|----------|------------|------------|------------|
|                               |         | Mean     | SD         | Mean       | SD         | Mean       | SD         |
| Red blood cells (×10E12/l)    | F       | 4.8      | 0.3        | 4.9        | 0.4        | 4.9        | 0.4        | 4.9        | 0.4        |
|                               | NF      | 4.9      | 0.3        | 4.9        | 0.4        | 5          | 0.4        | 4.9        | 0.3        |
| Haemoglobin (g/l)             | F       | 14.1     | 1          | 14.2       | 1.2        | 14.3       | 1          | 14.1       | 1.1        |
|                               | NF      | 14.2     | 1.1        | 14.2       | 1.1        | 14.3       | 1          | 14.1       | 1.2        |
| Haematocrit (%)               | F       | 41.2     | 3.5        | 41.5       | 3.3        | 41.5       | 3.1        | 41.6       | 3.2        |
|                               | NF      | 41.8     | 2.6        | 41.5       | 3.2        | 42         | 3          | 41.7       | 3.2        |
| Platelets (×10E9/l)           | F       | 299      | 42         | 318.2      | 71.6       | 303.9      | 72.1       | 317.4      | 79.2       |
|                               | NF      | 304.1    | 84.7       | 314.3      | 68.5       | 294.9      | 68.2       | 315.3      | 79.2       |
| White Blood Cells (×10E9/l)   | F       | 6.7      | 1.3        | 6.8        | 2.1        | 6.8        | 1.2        | 7          | 1.8        |
|                               | NF      | 6.5      | 1.2        | 6.9        | 1.6        | 6.6        | 1.6        | 6.6        | 1.4        |
| Neutrophils (×10E9/l)         | F       | 3.7      | 0.9        | 3.7        | 1.8        | 3.7        | 1          | 3.9        | 1.3        |
|                               | NF      | 3.5      | 1.1        | 3.9        | 1.3        | 3.6        | 1.4        | 3.5        | 0.9        |
| Alanine transaminase (U/l)    | F       | 30.7     | 26.6       | 34.4       | 32.5       | 32.8       | 34.8       | 29.7       | 31.8       |
|                               | NF      | 22.5     | 19.2       | 19.5       | 12.6       | 20.7       | 10.5       | 31.7       | 21.3       |
| Aspartic transaminase (U/l)   | F       | 28.9     | 12.1       | 27.5       | 11.2       | 27.7       | 13.2       | 26.3       | 13.7       |
|                               | NF      | 22.3     | 9.3        | 25         | 13.3       | 22.8       | 4.9        | 26.7       | 10.2       |
| Alkaline phosphatase (U/l)    | F       | 80.1     | 12.1       | 79.1       | 17.1       | 74.7       | 17.9       | 74.7       | 15.2       |
|                               | NF      | 69.5     | 14.4       | 70.7       | 15.7       | 75.7       | 15         | 75.6       | 15.5       |
| Calcium (nmol/l)              | F       | 2.4      | 0.1        | 2.4        | 0.2        | 2.4        | 0.1        | 2.5        | 0.1        |
|                               | NF      | 2.4      | 0.1        | 2.4        | 0.1        | 2.5        | 0.1        | 2.4        | 0.1        |
| Potassium (nmol/l)            | F       | 4        | 0.4        | 4.1        | 0.4        | 4.1        | 0.3        | 4.1        | 0.3        |
|                               | NF      | 4        | 0.4        | 4.3        | 0.6        | 4          | 0.2        | 4.1        | 0.3        |
| Sodium (nmol/l)               | F       | 140.7    | 2.7        | 136.5      | 1.8        | 137.9      | 2.1        | 141.7      | 1.6        |
|                               | NF      | 139.6    | 2.7        | 137.2      | 3.6        | 137.8      | 2.3        | 141.1      | 1.7        |
| Uric acid (mmol/l)            | F       | 361.8    | 64.6       | 361.8      | 74.6       | 357.4      | 80.5       | 345.1      | 53.7       |
|                               | NF      | 352.2    | 46         | 353.9      | 56.4       | 358.4      | 55.1       | 347.8      | 54.1       |
| Creatinine (mmol/l)           | F       | 104.5    | 13.1       | 107.4      | 13.1       | 102.2      | 11.4       | 103.3      | 12.2       |
|                               | NF      | 102.3    | 12.5       | 99.9       | 10.1       | 103.9      | 11.2       | 104.6      | 12.6       |

NF, Non-fixed combination; F, fixed combination
It is important to appreciate that the tested hypothesis is stated as the “alternative” hypothesis; the null hypothesis is rejected in favour of the alternative hypothesis if there is sufficient statistical evidence against the null hypothesis. With the Schuirmann two one-sided tests, this is broken down into two one-sided hypotheses (above and below the allowed range), and two separate t-tests are applied. For two products to be considered bioequivalent, the null hypothesis of bioinequivalence must be rejected (the test must be significant, normally with $\alpha=0.05$).

In general, the metrics we obtained with the fixed combination were well within the variance of the non-fixed combination. However, the strict criteria of bioequivalence were not met entirely. The mean geometric mean ratios for the AUCs obtained with the fixed versus non-fixed were 92 and 86% for total DHA and DEAQ, respectively; when the individual subjects’ Cmax were compared, the corresponding mean values were 102 and 107%, respectively. The 90% CI around the geometric least squares means ratios of the AUC with the fixed product over the non-fixed formulation were within the upper bound, but below the lower bound (78 and 62% for total DHA and DEAQ, respectively).

Irrespective of the discussion concerning the bioequivalence of the fixed and non-fixed formulation of AQ and AS, this study still adds to the currently limited information on the disposition of AQ. Two recent studies have reported considerably different pharmacokinetic characteristics of AQ [23, 24]. These differences, however, could be ascribed to different subject populations, disease effect and analytical assays: one study measured DEAQ in children with malaria from Papua New Guinea treated with AQ (10 mg/kg) for 3 days [23]; the other study investigated South African adult healthy volunteers given a single dose of AQ alone (10 mg/kg) [24]. The South Africa paper also reported the effects of co-administering AS and AQ with a three-phase cross-over design. This co-administration resulted in an approximately 35% reduction of the AUC for both drugs. Exposure to AS + AQ (measured by Cmax and AUC) in the adult healthy volunteers was approximately one-third of the AUC obtained with the fixed and non-fixed combination. The major question, then, is whether this lack of strictly defined bioequivalence is clinically relevant in patients. Comparison with biological data indicates that these differences are not expected to alter clinical responses in patients. Indeed, looking at available clinical data, a randomised controlled trial with a non-inferiority design comparing the loose and fixed-dose combinations has found similar efficacy rates for both combinations in paediatric falciparum malaria in Burkina-Faso [20]. The 80–125% limits for bioequivalence should also be based on the therapeutic window and pharmacokinetic/pharmacodynamic characteristics of a drug and should thus consider safety as well as efficacy [17]. For both drugs, and particularly AQ, which may have an increased risk of toxicity with higher doses [21, 22], exposure with the fixed formulation is well within the upper limit of acceptance. It should also be noted that the dose of AQ in the non-fixed combination was 13% higher than that in the fixed combination owing to different tablet strengths and that the data were not normalised by body weight in these analyses.

For AS + AQ and other currently available ACTs, the selection of combination treatment doses has been largely empirical, aiming to achieve the same doses as if given individually. The dose–response relationship for AS has been described [26], but there is currently very little information, especially in malaria patients, on the pharmacokinetic/pharmacodynamic properties of AQ or the AS +
AQ combination. A recent study exploring data from children in Zanzibar and Papua New Guinea derived the population kinetics of DEAQ and found a significant but weak correlation between the levels of DEAQ on Day 7 and antimalarial efficacy [27].

In clinical trials of uncomplicated falciparum malaria, co-administration of AS + AQ has been shown to be more effective than AQ alone [28] and is generally effective across Africa, although with regional variations, depending on the sensitivity of the local parasite strains to AQ [29]. Since the majority of these studies were conducted with individually formulated AS and AQ, which were either the same products as those used here for reference or equivalent products, combining the two drugs into a single tablet can be expected to produce the same clinical results, given that the levels of exposure achieved in this study were similar.

With respect to AS, the main disposition parameters were similar to those of a previous study in Malaysian volunteers following a single oral dose of 200 mg [30]. The AS + AQ combination was well tolerated, and only minor changes in safety parameters occurred, although the sample size was too small to detect rare events. In particular, there was no indication of liver or haematological toxicity, the two toxicities that have caused fatalities in the past when AQ was used as prophylaxis [31]. Although the number of healthy subjects was limited, each was exposed twice to AQ and followed for a long time. It has been suggested that repeat exposure to AQ may favour toxicity through the formation of a quinonemin that may lead to immunoglobulin G immune-mediated liver and neutrophil toxicity. Asymptomatic, self-resolving hepatitis was reported in a healthy female subject in the South African study [32]. Clinicians should be wary of this possibility in clinical practice.

With the wider use of the new fixed-dose AS + AQ combination, further studies on the disposition of these compounds in malaria patients are warranted, and safety should continue to be monitored.

Acknowledgments This study was funded by the Drugs for Neglected Diseases initiative (DNDi) with the contribution of a European Union INCO/DEV grant. We wish to thank the participating volunteers and Ann-Marie Sevscik for editing the manuscript.

Disclaimer P. Olliaro is a staff member of the World Health Organisation. The author alone is responsible for the views expressed in this publication, and they do not necessarily represent the decisions, policy, or views of the World Health Organisation.

Roles of authors The authors have full control of all primary data and agree to allow the European Journal of Clinical Pharmacology to review their data if requested.

- V. Navaratnam was the Principal Investigator of the study. He contributed to the concept, protocol, analysis, and reporting of the study as well as the preparation of the manuscript.
- S. Ramanathan contributed personally to the study design and conducted the pharmacokinetic analyses
- M. Suhaime Ab. Wahab participated in designing the concept and protocol of the study and supervised the clinical study conduct. He contributed personally to the treatment and follow-up of subjects.
- G. Siew Hua contributed personally to the treatment and follow-up of subjects.
- S. Mahsuri Mansor contributed to the supervision of the bioanalysis of samples.
- J-R. Kiechel contributed to concept of the project and critically reviewed the reporting of results.
- M. Vaillant designed and conducted analyses and contributed to the preparation of the manuscript.
- W.R.J. Taylor contributed to the clinical and safety-related aspects of protocol development, monitored the study and critically reviewed the manuscript.
- P. Olliaro contributed to the concept of the project, design of the protocol and analyses, reporting of the study and to the preparation of the manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. World Health Organisation (2008) World Malaria Report 2008 WHO/HTM/MAL/2008.1 World Health Organisation, Geneva. Available at: http://www.who.int/malaria/wmr2008/. Cited 12 Feb 2009
2. World Health Organisation (2006) Guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108. World Health Organisation, Geneva. Available at: http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf. Cited 17 July 2008.
3. White NJ, Olliaro PL (1996) Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 12:399–401
4. Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P, Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F (2000) Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg 94:537–544
5. Khanh NX, de Vries PJ, Ha LD, van Bokel CJ, Koopmans R, Kager PA (1999) Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for Falciparum malaria. Antimicrob Agents Chemother 43:690–692
6. Newton PN, van Vugt M, Teja-Isavadharm P, Sirianonda D, Rasameesoroj M, Teerapong P, Ruangveerayuth R, Slight T, Nosten F, Suputtamongkol Y, Looareesuwan S, White NJ (2002) Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute Falciparum malaria. Antimicrob Agents Chemother 46:1125–1127
7. Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, White N (2000) Antimalarial bioavailability and disposition of artesunate in acute Falciparum malaria. Antimicrob Agents Chemother 44:972–977
8. Suputtamongkol Y, Newton PN, Angus B, Teja-Isavadharm P, Keeratibakul D, Rasameesoroj M, Pukrittayakamee S, White NJ (2001) A comparison of oral artesunate and artemether antimalarial bioactivities in acute Falciparum malaria. Br J Clin Pharmacol 52:655–661
9. Li XQ, Björkman A, Andersson TB, Riddlerström M, Masimirembwa CM (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399–407
10. Winstanley PA, Simooya O, Kofi-Ekue JM, Walker O, Salako LA, Edwards G, Orme ML, Breckenridge AM (1990) The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol 33:695–701
11. Pussard E, Verdier F, Faurisson F, Scherrmann JM, Le Bras J, Blayo MC (1987) Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Pharmacol 33:331–333
12. Winstanley PA, Edwards G, Orme ML, Breckenridge AM (1987) Effect of dose size on amodiaquine pharmacokinetics after oral administration. Eur J Clin Pharmacol 33:331–333
13. Navaratnam V, Mordi MN, Mansor SM (1997) Simultaneous determination of artesunic acid and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. J Chromatogr B Biomed Sci Appl 692:157–162
14. Rowland M, Tozer T (1989) Clinical pharmacokinetics: concepts and applications, 2nd edn. Lea & Febiger, Philadelphia
15. Statistical Solutions (1998) EquivTest 1.0 user reference. Statistical Solutions, Cork, Ireland
16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Washington D.C. Available at: http://www.fda.gov/cder/Guidance/3616fnl.pdf. Cited 17 July 2008
17. Committee for Proprietary Medicinal Products (2001). Note for guidance on the investigation of bioavailability and bioequivalence. The European Agency for the Evaluation of Medicinal Products, Basel. Available at: http://www.emea.europa.eu/pdfs/human/qwp/140198en.pdf. Cited 17 July 2008
18. Teja-Isavadharm P, Peggins JO, Brewer TG, White NJ, Webster HK, Kyle DE (2004) Plasmodium falciparum-based bioassay for measurement of artemisinin derivatives in plasma or serum. Antimicrob Agents Chemother 48:954–960
19. Noedl H, Se Y, Schaecker K, Smith BL, Sochet D, Fukuda MM (2001) Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359(24):2619–2620
20. Sirimi et al; Submitted to
21. Brasseur P, Agramanye P, Gaye O, Vaillant M, Taylor WR, Olliaro PL (2007) Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Senegal. Malar J 6:150
22. Brasseur P, Agramanye P, Gaye O, Cisse M, Badiane M, Vaillant M, Taylor WR, Olliaro P (2009) Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop Med Int Health 14(1):79–87
23. Hombhanje FW, Hwaithwanje I, Tsukahara T, Saruwatari J, Nakagawa M, Osawa H, Paniu MM, Takahashi N, Lum JK, Aumora B, Masta A, Sapuri M, Kobayakawa T, Kaneko A, Ishizaki T (2005) The disposition of oral amodiaquine in Papua New Guinean children with Falciparum malaria. Br J Clin Pharmacol 59:298–301
24. Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, Barnes KI (2008) Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol 64:683–690
25. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL (2007) Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 82:197–203
26. Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ (2002) Oral artesunate dose-response relationship in acute Falciparum malaria. Antimicrob Agents Chemother 46:778–782
27. Hietala SF, Bhattarai A, Msellem M, Roshhammar D, Ali AS, Stromberg J, Hombhanje FW, Kaneko A, Björkman A, Ashton M (2007) Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated Falciparum malaria. J Pharmacokinet Pharmacodyn 34:669–686
28. Adjuik M, Agramanye P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR (2002) Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomized multicentre trial. Lancet 359:1365–1370
29. Olliaro P, Vaillant M, Phalkey R, Guthmann JP, Dorsey G, Brasseur P, D’Alessandro U, Millet P, Taylor WRJ (2006) Artesunate + amodiaquine (AS + AQ) for the treatment of uncomplicated falciparum malaria: an inventory and systematic review of safety and efficacy data. Presented at 12th Int Soc Infect Dis. Lisbon, Portugal, pp. 15–18
30. Navaratnam V, Mansor SM, Mordi MN, Akbar A, Abdullah MN (1998) Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers. Eur J Clin Pharmacol 54:411–414
31. Taylor WR, White NJ (2004) Antimalarial drug toxicity: a review. Drug Saf 27:25–61
32. Orrell C, Taylor WR, Olliaro P (2001) Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. Trans R Soc Trop Med Hyg 95:517–518